Disruptions to funding and new policies aimed at aligning foreign aid programs with the Trump administration’s agenda have ...

ViiV Healthcare’s Dovato has been approved for use in the US and EU since 2019, but its sales remain overshadowed by Gilead’s Biktarvy.

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced data to be presented this week at the 26 th International AIDS Conference ...

Study reveals that 77% of US partners had to adapt their work to Washington’s latest policies, with conditions surrounding ...

A 2023 meta analysis of 28 observational studies found the odds ratio of having prevalent hearing loss was 4.22 for metabolic ...

A new research study examining the scale of disruptions to HIV programmes caused by funding cuts from the United States’ ...

By Jennifer Rigby and Vincent Mumo Nzilani LONDON/NAIROBI, July 21 (Reuters) - Around 77,000 fewer children worldwide ...

People with hearing loss who received a hearing-aid prescription faced a 5.0 percent chance of developing dementia over seven ...

Around 77,000 fewer children worldwide received HIV treatment supported by the U.S. since October 2025 than in the previous ...

Democratic states and the Trump administration are clashing over a key part of a new federal rule imposing work requirements within Medicaid.

A new antiretroviral combination pill that is taken only once a week appears to work as well as daily pills at treating HIV. This is according to interim study findings to be presented next week at ...

Studies revealing the real-world impact of disruptions to the US President’s Emergency Plan for AIDS Relief (PEPFAR) and important advances in long-acting HIV prevention and treatment were announced ...